Skip to content

Study · In vitro (cells) · 2025

2 results

The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis.

Glinka DM, MacGregor GG

JID innovations : skin science from molecules to population health3 Apr 2025Cited by 1 (Europe PMC)

PMID40330848 (opens in a new tab)PMCIDPMC12051560 (opens in a new tab)DOI10.1016/j.xjidi.2025.100369 (opens in a new tab)PepBankPUB-40330848
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In keratinocyte monolayers, larazotide increased electrical resistance after histamine challenge.

    In plain wordsIn cells, larazotide increased electrical resistance after histamine challenge.

    Peptide
    Larazotide
    Outcome
    IncreaseElectrical resistance after histamine challenge
    Study

    humann: not reported in source

    normal human epithelial keratinocyte monolayers
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Larazotide mitigated the disruptive effect of histamine on epithelial permeability by increasing the electrical resistance and decreasing epithelial permeability.
    2 context sentences
    Summary · context
    Normal human epithelial keratinocytes were grown in culture on permeable supports.
    Summary · context
    The effects of larazotide on transepithelial resistance and permeability properties of keratinocyte monolayers were studied before and after histamine challenge.
  2. 02LabIn vitro (cells)Activity measurement

    In keratinocyte monolayers, larazotide decreased epithelial permeability after histamine challenge.

    In plain wordsIn cells, larazotide reduced epithelial permeability after histamine challenge.

    Peptide
    Larazotide
    Outcome
    DecreaseEpithelial permeability after histamine challenge
    Study

    humann: not reported in source

    normal human epithelial keratinocyte monolayers
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Larazotide mitigated the disruptive effect of histamine on epithelial permeability by increasing the electrical resistance and decreasing epithelial permeability.
    2 context sentences
    Summary · context
    Normal human epithelial keratinocytes were grown in culture on permeable supports.
    Summary · context
    The effects of larazotide on transepithelial resistance and permeability properties of keratinocyte monolayers were studied before and after histamine challenge.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.